Skip to main content

Advertisement

SpringerLink
Log in

Cholangiocarcinoma: State of the Art

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Cholangiocarcinoma (CCA) is the second most frequent primary liver tumor and defined as the heterogeneous group of tumors derived from cells in the biliary tree.

Methods and Results

Based on the anatomical locations (intrahepatic, perihilar, and distal), there are various approaches to the diagnosis and treatment of CCA. Imaging modalities, staging classifications, understandings around natural behavior of CCA, and therapeutic strategies have had remarkable progress in recent years.

Conclusions

This article reviews and discusses the epidemiology, clinical presentation, diagnosis, and treatment modalities of CCA; determines the appropriate inclusion and exclusion criteria for liver transplantation (LT); and defines the risk of disease progression for patients in the waiting list of LT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Zamora-Valdes D, Heimbach JK. Liver transplant for cholangiocarcinoma. Gastroenterol Clin. 2018;47(2):267–80.

    Article  Google Scholar 

  2. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261.

    Article  PubMed  Google Scholar 

  3. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–29.

    Article  CAS  PubMed  Google Scholar 

  4. Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Reports. 2019.

  5. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part III: liver, biliary tract, and pancreas. Gastroenterology. 2009;136(4):1134–44.

    Article  PubMed  Google Scholar 

  6. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology. 2011;54(1):173–84.

    Article  CAS  PubMed  Google Scholar 

  7. Blechacz B. Cholangiocarcinoma: current knowledge and new developments. Gut Liver. 2017;11(1):13–26.

    Article  PubMed  Google Scholar 

  8. Kirstein MM, Vogel A. Epidemiology and risk factors of cholangiocarcinoma. Visc Med. 2016;32(6):395–400.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Rizvi S, Gores GJ. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion. 2014;89(3):216–24.

    Article  CAS  PubMed  Google Scholar 

  10. Qureshi K, Jesudoss R, Al-Osaimi AM. The treatment of cholangiocarcinoma: a hepatologist's perspective. Curr Gastroenterol Rep. 2014;16(10):412.

    Article  PubMed  Google Scholar 

  11. Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra-and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006;98(12):873–5.

    Article  PubMed  Google Scholar 

  12. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–62.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Bragazzi MC, Cardinale V, Carpino G, Venere R, Semeraro R, Gentile R, et al. Cholangiocarcinoma: epidemiology and risk factors. Transl Gastrointest Cancer. 2011;1(1):21–32.

  14. Sullivan JI, Rockey DC. Diagnosis and evaluation of hyperbilirubinemia. Curr Opin Gastroenterol. 2017;33(3):164–70.

    Article  CAS  PubMed  Google Scholar 

  15. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(9):512–22.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lozada ME, Chaiteerakij R, Roberts LR. Screening for hepatocellular carcinoma and cholangiocarcinoma: can biomarkers replace imaging? Curr Hepatol Rep. 2015;14(2):128–38.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Morimoto Y, Tanaka Y, Ito T, Nakahara M, Nakaba H, Nishida T, et al. Long-term survival and prognostic factors in the surgical treatment for intrahepatic cholangiocarcinoma. J Hepato-Biliary-Pancreat Surg. 2003;10(6):432–40.

    Article  Google Scholar 

  18. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.

    Article  PubMed  Google Scholar 

  19. Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Ann Oncol. 2014;25(12):2328–38.

    Article  CAS  PubMed  Google Scholar 

  20. Joo I, Lee JM, Yoon JH. Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology. 2018;288(1):7–13.

    Article  PubMed  Google Scholar 

  21. Brungs D, Aghmesheh M, Sjoquist K, Goldstein D. Systemic treatment in advanced biliary cancers: a multicenter Australian analysis and review. Asia Pac J Clin Oncol. 2017;13(5):e291–e7.

    Article  PubMed  Google Scholar 

  22. Galassi M, Iavarone M, Rossi S, Bota S, Vavassori S, Rosa L, et al. Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. Liver Int. 2013;33(5):771–9.

    Article  CAS  PubMed  Google Scholar 

  23. Vidili G, Sio I, D’Onofrio M, Mirk P, Bertolotto M, Schiavone C. SIUMB guidelines and recommendations for the correct use of ultrasound in the management of patients with focal liver disease. 2018.

    Google Scholar 

  24. Hennedige TP, Neo WT, Venkatesh SK. Imaging of malignancies of the biliary tract-an update. Cancer Imaging. 2014;14(1):14.

    PubMed  PubMed Central  Google Scholar 

  25. Williamson J, Draganov P. The usefulness of SpyGlass™ choledochoscopy in the diagnosis and treatment of biliary disorders. Curr Gastroenterol Rep. 2012;14(6):534–41.

    Article  CAS  PubMed  Google Scholar 

  26. Laleman W, Verraes K, Van Steenbergen W, Cassiman D, Nevens F, Van der Merwe S, et al. Usefulness of the single-operator cholangioscopy system SpyGlass in biliary disease: a single-center prospective cohort study and aggregated review. Surg Endosc. 2017;31(5):2223–32.

    Article  PubMed  Google Scholar 

  27. Labib PL, Davidson BR, Sharma RA, Pereira SP. Locoregional therapies in cholangiocarcinoma. Hepat Oncol. 2017;4(4):99–109.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Olthof SC, Othman A, Clasen S, Schraml C, Nikolaou K, Bongers M. Imaging of cholangiocarcinoma. Visc Med. 2016;32(6):402–10.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Abolhassani H, Kiaee F, Tavakol M, Chavoshzadeh Z, Mahdaviani SA, Momen T, et al. Fourth update on the Iranian National Registry of Primary Immunodeficiencies: integration of molecular diagnosis. J Clin Immunol. 2018;38(7):816–32.

    Article  PubMed  Google Scholar 

  30. Mar WA, Shon AM, Lu Y, Jonathan HY, Berggruen SM, Guzman G, et al. Imaging spectrum of cholangiocarcinoma: role in diagnosis, staging, and posttreatment evaluation. Abdom Radiol (NY). 2016;41(3):553–67.

    Article  Google Scholar 

  31. Zhang H, Zhu J, Ke F, Weng M, Wu X, Li M, et al. Radiological imaging for assessing the respectability of hilar cholangiocarcinoma: a systematic review and meta-analysis. Biomed Res Int. 2015;2015.

  32. Ruys A, Van Beem B, Engelbrecht M, Bipat S, Stoker J, Van Gulik T. Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis. Br J Radiol. 2012;85(1017):1255–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Jhaveri KS, Hosseini-Nik H. MRI of cholangiocarcinoma. J Magn Reson Imaging. 2015;42(5):1165–79.

    Article  PubMed  Google Scholar 

  34. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park J-W, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.

    Article  PubMed  Google Scholar 

  35. Hamilton SR, Aaltonen LA. WHO classification of tumours. Pathology and genetics of tumours of the digestive system. Geneva: World health organization; 2000.

    Google Scholar 

  36. Goodman ZD. Neoplasms of the liver. Mod Pathol. 2007;20(1s):S49.

    Article  PubMed  Google Scholar 

  37. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9.

    Article  PubMed  Google Scholar 

  38. Konstadoulakis MM, Roayaie S, Gomatos IP, Labow D, Fiel M-I, Miller CM, et al. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery. 2008;143(3):366–74.

    Article  PubMed  Google Scholar 

  39. Yoshida T, Matsumoto T, Sasaki A, Morii Y, Aramaki M, Kitano S. Prognostic factors after pancreatoduodenectomy with extended lymphadenectomy for distal bile duct cancer. Arch Surg. 2002;137(1):69–73.

    Article  PubMed  Google Scholar 

  40. Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J, et al. Prognostic factors of surgical resection in middle and distal bile duct cancer: an analysis of 55 patients concerning the significance of ductal and radial margins. Surgery. 2005;137(4):396–402.

    Article  PubMed  Google Scholar 

  41. Lee HM, Jeong Y-I, Kim DH, Kwak TW, Chung C-W, Kim CH, et al. Ursodeoxycholic acid-conjugated chitosan for photodynamic treatment of HuCC-T1 human cholangiocarcinoma cells. Int J Pharm. 2013;454(1):74–81.

    Article  CAS  PubMed  Google Scholar 

  42. Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study–the UK ABC-01 study. Br J Cancer. 2009;101(4):621–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Konstantinidis IT, Arkadopoulos N, Ferrone CR. Surgical management of intrahepatic cholangiocarcinoma in the modern era: advances and challenges. Chin Clin Oncol. 2016;5(1):9.

    PubMed  Google Scholar 

  44. Ortner ME, Caca K, Berr F, Liebetruth J, Mansmann U, Huster D, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology. 2003;125(5):1355–63.

    Article  PubMed  Google Scholar 

  45. Ibarra RA, Rojas D, Snyder L, Yao M, Fabien J, Milano M, et al. Multicenter results of stereotactic body radiotherapy (SBRT) for non-resectable primary liver tumors. Acta Oncol. 2012;51(5):575–83.

    Article  PubMed  Google Scholar 

  46. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.

    Article  CAS  PubMed  Google Scholar 

  47. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Morizane C, Okusaka T, Mizusawa J, Katayama H, Ueno M, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: a Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). J Clin Oncol. 2018;36(4_suppl):205.

    Article  Google Scholar 

  49. Andre T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, et al. Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008;99(6):862–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016;27(1):134–40.

    Article  CAS  PubMed  Google Scholar 

  51. Peixoto RD, Renouf D, Lim H. A population based analysis of prognostic factors in advanced biliary tract cancer. J Gastrointest Oncol. 2014;5(6):428–32.

    PubMed  PubMed Central  Google Scholar 

  52. Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11(1):48–54.

    Article  CAS  PubMed  Google Scholar 

  53. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, et al. Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005;23(10):2332–8.

    Article  CAS  PubMed  Google Scholar 

  54. Iqbal S, Rankin C, Lenz H-J, Gold PJ, Ahmad SA, El-Khoueiry AB, et al. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: southwest oncology group study S0202. Cancer Chemother Pharmacol. 2011;68(6):1595–602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(12):1707–12.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5(6):824–30.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96(6):896–902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Phelip J-M, Edeline J, Blanc J-F, Barbier E, Michel P, Bourgeois V, et al. Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: study protocol for a randomized controlled multicenter phase II/III study. Dig Liver Dis. 2019;51(2):318–20.

    Article  CAS  PubMed  Google Scholar 

  59. Choi CW, Choi IK, Seo JH, Kim BS, Kim JS, Kim CD, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol. 2000;23(4):425–8.

    Article  CAS  PubMed  Google Scholar 

  60. Kobayashi S, Ueno M, Sugimori K, Morizane C, Kojima Y, Irie K, et al. Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer. Cancer Chemother Pharmacol. 2017;80(6):1189–96.

    Article  CAS  PubMed  Google Scholar 

  61. Jung JH, Lee HS, Jo JH, Cho IR, Chung MJ, Bang S, et al. Combination therapy with capecitabine and cisplatin as second-line chemotherapy for advanced biliary tract cancer. Chemotherapy. 2017;62(6):361–6.

    Article  CAS  PubMed  Google Scholar 

  62. Kim R, Chiorean EG, Amin M, Rocha-Lima CMS, Gandhi J, Harris WP, et al. Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment. Br J Cancer. 2017;117(2):189–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Fornaro L, Cereda S, Aprile G, Di Girolamo S, Santini D, Silvestris N, et al. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer. 2014;110(9):2165–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, Ryoo BY, et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer. 2017;116(5):561–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J Clin Oncol. 2019;37(15_suppl):4003.

    Article  Google Scholar 

  66. O'Neil BH, Wallmark J, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. 502 pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): preliminary results from KEYNOTE-028. Eur J Cancer. 2015;51:S103.

    Article  Google Scholar 

  67. Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev. 2015;41(10):868–76.

    Article  CAS  PubMed  Google Scholar 

  68. Gani F, Nagarajan N, Kim Y, Zhu Q, Luan L, Bhaijjee F, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2016;23(8):2610–7.

    Article  PubMed  Google Scholar 

  69. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients1. Transplantation. 2000;69(8):1633–7.

    Article  CAS  PubMed  Google Scholar 

  70. Rosen C, Heimbach J, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. Hpb. 2008;10(3):186–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Murad SD, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA, et al. Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology. 2012;56(3):972–81.

    Article  Google Scholar 

  72. Facciuto ME, Singh MK, Lubezky N, Selim MA, Robinson D, Kim-Schluger L, et al. Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation. Transplantation. 2015;99(1):151–7.

    Article  PubMed  Google Scholar 

  73. Fu Y, Yang W, Wu W, Yan K, Xing B-c, Chen M-h. Radiofrequency ablation for postoperative recurrences of intrahepatic cholangiocarcinoma. Chin J Cancer Res. 2011;23(4):295–300.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg. 2011;146(6):683–9.

    Article  PubMed  Google Scholar 

  75. Shimoda M, Farmer DG, Colquhoun SD, Rosove M, Ghobrial RM, Yersiz H, et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl. 2001;7(12):1023–33.

    Article  CAS  PubMed  Google Scholar 

  76. De Vreede I, Steers JL, Burch PA, Rosen CB, Gunderson LL, Haddock MG, et al. Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoradiation for cholangiocarcinoma. Liver Transpl. 2000;6(3):309–16.

    Article  PubMed  Google Scholar 

  77. Heimbach JK, Gores GJ, Nagorney DM, Rosen CB. Liver transplantation for perihilar cholangiocarcinoma after aggressive neoadjuvant therapy: a new paradigm for liver and biliary malignancies? Surgery. 2006;140(3):331–4.

    Article  PubMed  Google Scholar 

  78. Sia D, Tovar V, Moeini A, Llovet J. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene. 2013;32(41):4861–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Chng KR, Chan SH, Ng AHQ, Li C, Jusakul A, Bertrand D, et al. Tissue microbiome profiling identifies an enrichment of specific enteric bacteria in Opisthorchis viverrini associated cholangiocarcinoma. EBioMedicine. 2016;8:195–202.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Mertens JC, Fingas CD, Christensen JD, Smoot RL, Bronk SF, Werneburg NW, et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 2013;73(2):897–907.

    Article  CAS  PubMed  Google Scholar 

  81. Borad MJ, Champion MD, Egan JB, Liang WS, Fonseca R, Bryce AH, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  82. Kisiel JB, Dukek BA, V S R Kanipakam R, Ghoz HM, Yab TC, Berger CK, et al. Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation. Hepatology. 2019;69(3):1180–92.

  83. Takahashi M, Wakabayashi G, Nitta H, Takeda D, Hasegawa Y, Takahara T, et al. Pure laparoscopic right hepatectomy by anterior approach with hanging maneuver for large intrahepatic cholangiocarcinoma. Surg Endosc. 2013;27(12):4732–3.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Liver Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran

    Bobak Moazzami, Arash Dooghaie-Moghadam, Niloofar Razavi-Khorasani, Farhad Shahi, Habibolah Dashti & Mohssen Nassiri Toosi

  2. Research Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran, Iran

    Keivan Majidzadeh-A, Shahrokh Iravani, Alireza Khoshdel & Azim Mehrvar

  3. Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

    Pegah Eslami

Authors
  1. Bobak Moazzami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keivan Majidzadeh-A
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arash Dooghaie-Moghadam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pegah Eslami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Niloofar Razavi-Khorasani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shahrokh Iravani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alireza Khoshdel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Farhad Shahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Habibolah Dashti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Azim Mehrvar
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mohssen Nassiri Toosi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Azim Mehrvar or Mohssen Nassiri Toosi.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moazzami, B., Majidzadeh-A, K., Dooghaie-Moghadam, A. et al. Cholangiocarcinoma: State of the Art. J Gastrointest Canc 51, 774–781 (2020). https://doi.org/10.1007/s12029-020-00390-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00390-3

Keywords

Search

Navigation